Frank C Albers (Frank Albers)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Body Mass Index

Chronic Obstructive Pulmonary Disease

Top Venues

Journal of asthma and allergy

The New England journal of medicine

Respiratory research

This page only lists publications with an associated author ORCID identifier.

Publications

Craig LaForce, Frank C Albers, Mark Cooper, Anna Danilewicz, Lynn Dunsire, Robert Rees, Christy Cappelletti
A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol-Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design. Journal of asthma and allergy 17 (2024)
Craig LaForce, Frank C Albers, Mark Cooper, Anna Danilewicz, Lynn Dunsire, Robert Rees, Christy Cappelletti
A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol-Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design. Journal of asthma and allergy 17 (2024)
Frank C Albers, Daniel J Bratton, Necdet B Gunsoy, Sarah M Cockle, Rafael Alfonso-Cristancho, Gert-Jan Braunstahl
Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. The clinical respiratory journal 16 (3) (2022)
Alberto Papi, Bradley E Chipps, Richard Beasley, Reynold A Panettieri, Elliot Israel, Mark Cooper, Lynn Dunsire, Allison Jeynes-Ellis, Eva Johnsson, Robert Rees, Christy Cappelletti, Frank C Albers
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. The New England journal of medicine 386 (22) (2022)
Charlene M Prazma, Marco Idzko, Jo Anne Douglass, Arnaud Bourdin, Stephen Mallett, Frank C Albers, Steven W Yancey
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes. Journal of asthma and allergy 14 (2021)
Peter J Howarth, Santiago Quirce, Alberto Papi, Elliot Israel, Stephen Mallett, Stewart Bates, Steve Yancey, Frank C Albers, Namhee Kwon
Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. Allergy 75 (8) (2020)
Marjolein Engelkes, Esmé J Baan, Maria A J de Ridder, Elisabeth Svensson, Daniel Prieto-Alhambra, Francesco Lapi, Carlo Giaquinto, Gino Picelli, Nada Boudiaf, Frank C Albers, Lee A Evitt, Sarah Cockle, Eric Bradford, Melissa K Van Dyke, Robert Suruki, Peter Rijnbeek, Miriam C J M Sturkenboom, Hettie M Janssens, Katia M C Verhamme
Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 31 (5) (2020)
Kenneth R Chapman, Frank C Albers, Bradley Chipps, Xavier Muñoz, Gilles Devouassoux, Miguel Bergna, Dmitry Galkin, Jay Azmi, Dalal Mouneimne, Robert G Price, Mark C Liu
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy 74 (9) (2019)
Frank C Albers, Alberto Papi, Camille Taillé, Daniel J Bratton, Eric S Bradford, Steven W Yancey, Namhee Kwon
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respiratory research 20 (1) (2019)
Frank C Albers, Soichiro Hozawa, Daniel J Bratton, Steven W Yancey, Charlene M Prazma, Marc Humbert, Mark C Liu
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Allergy 75 (4) (2019)